$2.23
1.36% yesterday
Nasdaq, Dec 24, 10:49 pm CET
ISIN
US14817C1071
Symbol
SAVA

Cassava Sciences, Inc. Stock price

$2.23
-0.67 23.10% 1M
+0.29 14.95% 6M
-0.13 5.51% YTD
-0.11 4.70% 1Y
-29.45 92.96% 3Y
-5.23 70.11% 5Y
-10.37 82.30% 10Y
-34.41 93.91% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.03 1.36%
ISIN
US14817C1071
Symbol
SAVA
Industry

Key metrics

Basic
Market capitalization
$107.7m
Enterprise Value
$1.7m
Net debt
positive
Cash
$106.1m
Shares outstanding
48.3m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.3
Financial Health
Equity Ratio
92.5%
Return on Equity
-16.7%
ROCE
-136.3%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-110.5m | -
EBIT
$-111.3m | $-99.3m
Net Income
$-106.0m | $-95.1m
Free Cash Flow
$-83.9m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
17.2% | -
EBIT
17.4% | 29.8%
Net Income
-500.4% | -290.7%
Free Cash Flow
-7.5%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-2.2
FCF per Share
$-1.7
Short interest
15.5%
Employees
30
Rev per Employee
$0.0
Show more

Is Cassava Sciences, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Cassava Sciences, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Cassava Sciences, Inc. forecast:

6x Buy
75%
2x Hold
25%

Analyst Opinions

8 Analysts have issued a Cassava Sciences, Inc. forecast:

Buy
75%
Hold
25%

Financial data from Cassava Sciences, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 68 68
2% 2%
-
- Research and Development Expense 43 43
36% 36%
-
-111 -111
17% 17%
-
- Depreciation and Amortization 0.80 0.80
33% 33%
-
EBIT (Operating Income) EBIT -111 -111
17% 17%
-
Net Profit -106 -106
500% 500%
-

In millions USD.

Don't miss a Thing! We will send you all news about Cassava Sciences, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Cassava Sciences, Inc. Stock News

Neutral
PRNewsWire
about 23 hours ago
Shareholders should contact the firm immediately as there may be limited time to enforce your rights.   NEW YORK , Dec. 24, 2025 /PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders.
Neutral
Business Wire
2 months ago
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether certain officers and directors of Cassava Sciences, Inc. (NASDAQ: SAVA) breached their fiduciary duties to shareholders. If you currently own Cassava stock and acquired shares on or before September 14, 2020, you may be able to seek corporate governance reforms, the return of funds back to the com...
Neutral
GlobeNewsWire
2 months ago
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA, “Cassava”, the “Company”), a biotechnology company focused on developing novel, investigational treatments for central nervous system (CNS) disorders such as Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced the appointment of Ms. Dawn C. Bir to its Board of Directors (the Board).
More Cassava Sciences, Inc. News

Company Profile

Cassava Sciences, Inc. engages in the development of novel drugs and diagnostics. It focuses on developing product candidates intended for the treatment of Alzheimer's disease, including PTI-125 and PTI-125Dx. The company was founded by Remi Barbier and Barry M. Sherman in May 1998 and is headquartered in Austin, TX.

Head office United States
CEO Mr. Barry
Employees 30
Founded 1998
Website www.cassavasciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today